SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing.
SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing.
复制标题
DOI：
10.1016/j.phrs.2016.03.013
复制
发表时间：
2016-05
影响因子：
9.3
通讯作者：
Oltean S
中科院分区：
文献类型：
--
作者：
Mavrou A;Oltean S
尽管过去 10 年人们对新疗法进行了大量研究和开发，但前列腺癌仍然是全世界男性癌症死亡的主要原因之一。尽管有强有力的证据表明血管生成的决定因素（例如血管内皮生长因子）与疾病进展密切相关，但迄今为止，已测试的新途径之一（抑制血管生成）在临床研究中仍令人失望。造成这些结果的原因之一可能是我们对前列腺癌（也可能还有其他癌症）血管生成的生物学了解不足，导致有害和有利分子的抑制。我们在这里讨论抑制前列腺癌血管生成的新的有针对性的和更具体的方法，以及一种全新的治疗方式⿿选择性剪接的调节⿿，这也可能适用于其他分子/生物过程。
Prostate cancer remains one of the leading causes of cancer death in men around the world, regardless of intense research and development of novel therapies in the last 10 years. One of the new avenues that has been tested ⿿ inhibition of angiogenesis ⿿ has been disappointing so far in clinical studies in spite of strong evidence that determinants of angiogenesis (e.g. vascular endothelial growth factor) are strongly associated with disease progression. One of the reasons for these outcomes may be our poor understanding of the biology of angiogenesis in prostate cancer (and probably other cancers as well) resulting in inhibition of both detrimental and favourable molecules. We discuss here novel targeted and more specific approaches to inhibit angiogenesis in prostate cancer as well as a completely new therapeutic modality to do this ⿿ modulation of alternative splicing ⿿ that may be applicable to other molecules/biological processes as well.